A new standard of care in muscle-invasive bladder Ca?
With a median follow-up of almost a decade, patients with muscle-invasive bladder cancer who had chemoradiotherapy had improved locoregional control and a reduced salvage cystectomy rate compared to those who had radiotherapy alone, according to research presented at the Genitourinary Cancers Symposium, Orlando, FL.
Chemoradiotherapy, with fluorouracil (5FU) and mitomycin, should be a standard of care for these patients, the study authors say.
The take-home message to urologists from the Cancer Research UK-funded phase III trial, according to co-lead author Professor Emma Hall, PhD, of the Institute of Cancer Research, London, is that chemoradiotherapy is an effective alternative to cystectomy in the primary management of muscle-invasive bladder cancer.
“Patients preserve their bladder and have good long-term quality of life outcomes,” she said.
Dr. Hall and colleagues studied 458 patients with muscle-invasive bladder cancer who received radiotherapy or chemoradiotherapy, and, for the radiotherapy comparison, standard radiotherapy versus reduced high-dose volume radiotherapy.